Literature DB >> 11486587

[Permeability of the round window membrane for prednisolone-21-hydrogen succinate. Prednisolone content of the perilymph after local administration vs. systemic injection].

G Bachmann1, J Su, C Zumegen, C Wittekindt, O Michel.   

Abstract

BACKGROUND AND
OBJECTIVE: Prednisolone is the drug of first choice for the treatment of cochleovestibular disorders, such as sudden hearing loss. Because of the known side effects, the efficient drug levels to be achieved within inner ear fluids are limited by intravenous administration. The aim of the study was to determine the concentration in the perilymph of prednisolone-21-hydrogen succinate applied into the round window niche in comparison to the concentration after intraperitoneal application.
METHODS: Application of prednisolone-21-hydrogen succinate (5 mg in 0.1 ml) on the round window membrane was performed after sedation under microscopic view directly into the round window niche of the guinea pig. In order to compare the results, perilymph samples after systemic application of 60 mg/kg body weight prednisolone were used. The time between application and taking specimens of perilymph from the cochlea varied. Specimens of perilymph were obtained after 15, 20, 80, 180, 330, and 960 min (10 specimens in each group, n = 60) by dissecting the cochlea and opening the apex cochleae. Levels of prednisolone-21-hydrogen succinate in perilymph were measured by isocratic high-pressure liquid chromatography (HPLC).
RESULTS: The highest levels of prednisolone-21-hydrogen succinate were found after 180 min: 952.3 mg/l (95% confidence interval: 382.7). After 960 min the level was 18.72 mg/l (95% confidence interval: 16.9). In the group with systemic application, the levels measured were below 14.71 mg/l (95% confidence interval: 7.05).
CONCLUSION: The results demonstrate that high levels of prednisolone-21-hydrogen succinate in perilymph are achievable by local application of a single dose into the round window niche. After application of 5 mg, the levels of prednisolone are measurable up to 16 h.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11486587     DOI: 10.1007/s001060170078

Source DB:  PubMed          Journal:  HNO        ISSN: 0017-6192            Impact factor:   1.284


  23 in total

1.  Therapy of hearing disorders - conservative procedures.

Authors:  Stefan Plontke
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2005-09-28

2.  Current aspects of hearing loss from occupational and leisure noise.

Authors:  S Plontke; H-P Zenner
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2004-12-28

3.  [Intratympanic glucocorticoid therapy of sudden hearing loss].

Authors:  S K Plontke
Journal:  HNO       Date:  2010-10       Impact factor: 1.284

Review 4.  Local inner-ear drug delivery and pharmacokinetics.

Authors:  Alec N Salt; Stefan K R Plontke
Journal:  Drug Discov Today       Date:  2005-10-01       Impact factor: 7.851

Review 5.  [Inquiries into local application of drugs on the inner ear. Innovation prize of the Working Group for German Speaking Audiologists and Neuro-otologists 2005].

Authors:  S Plontke
Journal:  HNO       Date:  2005-10       Impact factor: 1.284

Review 6.  Principles of local drug delivery to the inner ear.

Authors:  Alec N Salt; Stefan K Plontke
Journal:  Audiol Neurootol       Date:  2009-11-16       Impact factor: 1.854

7.  Transtympanic corticoid therapy for acute profound hearing loss.

Authors:  Jürgen Lautermann; Holger Sudhoff; Rüdiger Junker
Journal:  Eur Arch Otorhinolaryngol       Date:  2005-03-03       Impact factor: 2.503

8.  Rapid clearance of methylprednisolone after intratympanic application in humans. Comment on: Bird PA, Begg EJ, Zhang M, et al. Intratympanic versus intravenous delivery of methylprednisolone to cochlear perilymph. Otol Neurotol 2007;28:1124-30.

Authors:  Stefan K Plontke; Anthony A Mikulec; Alec N Salt
Journal:  Otol Neurotol       Date:  2008-08       Impact factor: 2.311

9.  Dexamethasone concentration gradients along scala tympani after application to the round window membrane.

Authors:  Stefan K Plontke; Thorsten Biegner; Bernd Kammerer; Ursular Delabar; Alec N Salt
Journal:  Otol Neurotol       Date:  2008-04       Impact factor: 2.311

10.  Cogan's syndrome: clinical evolution of deafness and vertigo in three patients.

Authors:  A Baumann; A Helbling; S Oertle; R Häusler; D Vibert
Journal:  Eur Arch Otorhinolaryngol       Date:  2004-03-05       Impact factor: 2.503

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.